4Izuishi K,Yamamoto Y,Sano T,et al.Impact of18-fluorodeoxyglucose positron emission tomography on the management of pancreatic cancer[J].J Gastrointest Surg,2010,14(7):1151-1158.
5Kauhanen SP,Komar G,Seppanen MP,et al.A prospective diagnostic accuracy study of 18F-fluorodeoxyghcose positron emission tomogryphy/computed tomography,multidetector row computed tomography,and magnetic resonance imaging in primary diagnosis and staging of pancreatic cancer[J].Ann Surg,2009,250(6):957-963.
6Kluetz PG,Meltzer CC,Villemage VL,et al.Combined PET/CT imaging in oncology.Impact on Patient Management[J].Clin Positron Imaging,2000,3(6):223-230.
7Black QC,Grills IS,Kestin LL,et al.Defining a radiotherapy target with positron emission tomography[J].Int J Radiat Oncol Biol Phys,2004,60(4):1272-1282.
8Reske SN,Grillenberger KG,Glatting G,et al.Overexpression of glucose transporter 1 and increased FDG uptake in pancreatic carcinoma[J].J Nucl Med,1997,38(9):1344-1348.
9Ahmedzai S.New approaches to pain control in patients with cancer[J].Eur J Cancer,1997,33 Suppl 6:S8-14.
